Cargando…

Targeting transglutaminase 2 as a potential disease modifying therapeutic strategy for synucleinopathies

Detalles Bibliográficos
Autores principales:	Zhang, Jie, Jasutkar, Hilary Grosso, Mouradian, M. Maral
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323704/ https://www.ncbi.nlm.nih.gov/pubmed/33433482 http://dx.doi.org/10.4103/1673-5374.303027

Ejemplares similares

Transglutaminase 2 Depletion Attenuates α-Synuclein Mediated Toxicity in Mice
por: Zhang, Jie, et al.
Publicado: (2020)

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
por: Outeiro, Tiago Fleming, et al.
Publicado: (2008)

Do Changes in Synaptic Autophagy Underlie the Cognitive Impairments in Huntington’s Disease?
por: Grosso Jasutkar, Hilary, et al.
Publicado: (2021)

Organotypic hippocampal slices, an emerging tool to model synucleinopathies
por: Elfarrash, Sara, et al.
Publicado: (2020)

Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective
por: Knecht, Luisa, et al.
Publicado: (2022)

The role of lysosomes in alpha-synucleinopathies: a focus on glial cells
por: Balta, Denise, et al.
Publicado: (2021)

Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo
por: Jeitner, Thomas M., et al.
Publicado: (2018)

Neuronal and endothelial transglutaminase-2 expression in experimental autoimmune encephalomyelitis and multiple sclerosis
por: Pearse, Damien D., et al.
Publicado: (2021)

Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
por: Menon, Sindhu, et al.
Publicado: (2022)

Is EAAT2 a potential therapeutic intervention target for Alzheimer’s disease?
por: Wood, Oliver WG, et al.
Publicado: (2023)

Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5’UTR of SARS-CoV-2
por: Baldassarre, Antonella, et al.
Publicado: (2020)

Neuroglial Senescence, α-Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson’s Disease
por: Miller, Sean J., et al.
Publicado: (2022)

Disease modifying effect of adiponectin in model of α-synucleinopathies
por: Sekiyama, Kazunari, et al.
Publicado: (2014)

Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy
por: Arnaldi, Dario, et al.
Publicado: (2021)

Gut microbiota: a potential therapeutic target for Parkinson’s disease
por: Baizabal-Carvallo, José Fidel
Publicado: (2020)

Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
por: Büchold, Christian, et al.
Publicado: (2022)

Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies
por: Lai, Thuy Thi, et al.
Publicado: (2023)

Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies
por: Ebrahimi-Fakhari, Darius, et al.
Publicado: (2013)

Transglutaminase 2 as a Marker for Inflammation and Therapeutic Target in Sepsis
por: Su, Ting, et al.
Publicado: (2021)

Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics
por: Pradeep, Sai Pallavi, et al.
Publicado: (2023)

TREM2 as an evolving therapeutic target in Alzheimer’s disease
por: George, Jacob
Publicado: (2023)

Vascular dysfunction in Alzheimer’s disease: a biomarker of disease progression and a potential therapeutic target
por: Govindpani, Karan, et al.
Publicado: (2019)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?
por: Roberts, Bradley, et al.
Publicado: (2022)

Immune inflammatory modulation as a potential therapeutic strategy of stem cell therapy for ALS and neurodegenerative diseases
por: Kim, Seung Hyun, et al.
Publicado: (2018)

Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets
por: Lorente-Gea, Laura, et al.
Publicado: (2017)

Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer
por: Cha, Pu-Hyeon, et al.
Publicado: (2016)

LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease
por: Hyun, Cheol Hwan, et al.
Publicado: (2013)

LIM kinases in synaptic plasticity and their potential as therapeutic targets
por: Halász, Éva, et al.
Publicado: (2020)

Inhibition of microglial activation and induction of neurotrophic factors by flavonoids: a potential therapeutic strategy against Parkinson's disease
por: Kim, Sang Ryong
Publicado: (2015)

A Novel Therapeutic Target in Inflammatory Uveitis: Transglutaminase 2 Inhibitor
por: Sohn, Joonhong, et al.
Publicado: (2010)

FBXO45 is a potential therapeutic target for cancer therapy
por: Lin, Min, et al.
Publicado: (2020)

The Conserved Macrodomain Is a Potential Therapeutic Target for Coronaviruses and Alphaviruses
por: Leung, Anthony K. L., et al.
Publicado: (2022)

Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders
por: Terada, Kazuki, et al.
Publicado: (2019)

Amyotrophic lateral sclerosis disease modifying therapeutics: a cell biological perspective
por: Tang, Bor Luen
Publicado: (2017)

Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: a new potential multi-target therapeutic strategy for the treatment of Alzheimer’s disease
por: Brunetti, Leonardo, et al.
Publicado: (2019)

Chronic lung disease, lung regeneration and future therapeutic strategies
por: Cao, Xuan-Ye, et al.
Publicado: (2018)

Current and future therapeutic strategies for the treatment of retinal neurodegenerative diseases
por: Maneu, Victoria, et al.
Publicado: (2021)

miR-124, a potential therapeutic target in colorectal cancer
por: Qin, Zhen, et al.
Publicado: (2019)

cGMP signaling: a potential therapeutic target for neurodegeneration in glaucoma?
por: Holden, Joseph M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_40g7om4e2bbrcciv66ucqp584t